Drug Trial Radar · NCT04498832
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older
Last checked: Nov 19, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,100
Actual
Start
Oct 21, 2020
Primary completion
Jan 14, 2021
Study completion Jan 14, 2021
Sponsor
- Lead sponsor
- Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Aug 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate that QIV-HD induced an immune response (as assessed by hemagglutination inhibition \[HAI\] geometric mean titers \[GMTs\] and seroconversion rates) that was superior to responses induced by QIV-SD for the 4 virus strains at 28 days post-vaccination in all participants. Secondary Objective: * To describe the immune response induced by QIV-HD and QIV-SD by HAI measurement method in all participants. * To describe the safety profile of all participants in each study group.
Conditions
- Influenza Immunization
- Healthy Volunteers
Interventions
High-Dose Quadrivalent Influenza Vaccine, (Zonal Purified, Split Virus) 2020-2021 Strains (QIV-HD)Biological
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Local Standard-Dose Inactivated Quadrivalent Influenza Vaccine, 2020-2021 Strains (QIV-SD)Biological
Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 28Time frame: Day 28 (post-vaccination)
- Percentage of Participants Achieving Seroconversion Against Influenza Virus Antigens: Superiority AnalysisTime frame: Day 28 (post-vaccination)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Investigational Site Number 3920005
Fukuoka, Japan
Investigational Site Number 3920004
Koganeishi, Japan
Investigational Site Number 3920006
Kumamoto, Japan
Investigational Site Number 3920001
Osaka, Japan
Investigational Site Number 3920003
Shinjuku-Ku, Japan
Investigational Site Number 3920008
Shinjuku-Ku, Japan
Investigational Site Number 3920009
Shinjuku-Ku, Japan
Investigational Site Number 3920002
Suita-Shi, Japan
Investigational Site Number 3920007
Toshima-Ku, Japan
Investigational Site Number 3920010
Yokohama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.